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512Imipenem/Cilastatin with or without Glycopeptide as
Initial Antibiotic Therapy for Recipients of Autologous
Stem Cell Transplantation: Results of a Spanish
Multicenter Study
Javier de la Rubia,1 Pau Montesinos,1 Rodrigo Martino,2 Isidro Jarque,1 Montserrat Rovira,3
Lourdes Vazquez,4 Javier Lopez,5 Montserrat Batlle,6 Rafael de la Camara,7 Antoni Julia,8
Juan J. Lahuerta,9 Guillermo Deben,10 Joaquin Dıaz,11 Raimundo Garcıa,12 Miguel A. Sanz1We analyzed the efficacy of imipenem/cilastatin alone (group I, 197 patients) or in combination with a glyco-
peptide (group I 1 G, 231 patients) as first-line antibiotic therapy for 2 consecutive cohorts of autologous
stem cell transplantation (ASCT) recipients with febrile neutropenia. From June 2001 to June 2002, patients
received imipenem/cilastatin (500 mg/6 hours), and from July 2002 to December 2003, they received imipe-
nem/cilastatin as for group I plus a glycopeptide (vancomycin, 1 g/12 hours or teicoplanin, 400 mg/day). Fever
of unknown origin accounted for 33.5% of episodes (66 patients) in group I and 50% of episodes (116 patients)
in group I 1 G (P 5 .005). Bacteremia occurred in 55 patients (28%) in group I and in 51 patients (22%) in
group I 1 G (P 5 .16). Resolution of fever without modification of the therapy regimen was observed in
108 patients (55%) and 159 patients (69%) in groups I and I1G, respectively (P5.003). The median interval
to defervescence (4 days) and overall mortality were similar between groups. Inclusion of a glycopeptide in
the initial antibiotic regimen for febrile neutropenia results in a higher success rate without modifying the
regimen. However, glycopeptide inclusion does not improve the interval to defervescence or mortality rate.
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Infection is a frequent complication among
patients undergoing an autologous stem cell transplan-
tation (ASCT) [1-6]. Early antibiotic therapy reduces
morbidity and mortality, and is standard practice for
ASCT recipients who exhibit fever and neutropenia.
The standard therapy for such patients is monotherapy
with a broad-spectrum antipseudomonal b-lactam
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6/j.bbmt.2008.12.505addition of a glycopeptide to b-lactam antibiotics as
initial therapy for neutropenic fever did not improve
therapy failure rate or mortality rate [8-10]. However,
these studies were carried out in heterogeneous popu-
lations of cancer patients who may not have been
exposed to risk factors for Gram-positive infection fre-
quently present in ASCT patients, such as severe
mucositis, the presence of central venous catheters,
and parenteral nutrition. To study the efficacy of anti-
microbial monotherapy and to assess the role of the
empirical use of anti-Gram-positive antibiotics for
febrile neutropenic patients undergoing ASCT, we
conducted an observational, prospective, multicenter
study using 2 consecutive cohorts of ASCT recipients
with febrile neutropenia to determine the efficacy of
imipenem/cilastatin alone (group I) compared with
imipenem/cilastatin plus a glycopeptide antibiotic
(group I 1 G).PATIENTS AND METHODS
Between June 2001 andDecember 2003, an opened,
comparative, unblinded, sequential, multicenter study
was conducted at 23 Spanish institutions ascribed to
Biol Blood Marrow Transplant 15:512-516, 2009 513Imipenem with or without Glycopeptide for ASCT Recipientsthe PETHEMA-GETH group (see Acknowledg-
ments). The trial was designed in accordance with
guidelines issuedby the ImmunocompromisedHostSo-
ciety (IHS) Consensus Conference and the European
Society of ClinicalMicrobiology and InfectiousDisease
(ESCMID) [11-13].
The study protocol was conducted in accordance
with the Declaration of Helsinki, and was approved
by the ethics committee of each participating institu-
tion; informed consent was provided by all patients
who fulfilled the inclusion criteria.
Patients undergoing ASCT were enrolled if they
met the following inclusion criteria: (1) hospitalized
patients aged 18 years and older; (2) an absolute gran-
ulocyte count\1  109/L after ASCT, which was an-
ticipated to decrease to\0.5  109/L within 24 to 48
hours; and (3) fever, defined as an axillary temperature
$38C on 2 occasions at least 1 hour apart, or 38.5C
on 1 occasion. Exclusion criteria were allergy to any of
the antibiotics used in the study (imipenem/cilastatin,
vancomycin, or teicoplanin) or a history of allergy to b-
lactam antibiotics, pregnant or breast-feeding women,
a serum creatinine level .200 mmol/L or a creatinine
clearance rate of\40 mL/min, concomitant i.v. treat-
ment with an antibiotic or i.v. administration of an an-
tibiotic within 96 hours of admission to the study, and
HIV infection.
Specimens for microbiologic analysis were ob-
tained before and during therapy, as clinically indi-
cated. Patients with suspected pneumonia were
subjected to bronchoalveolar lavage or fibrobroncho-
scopy brushing if possible. Samples for blood culture
were obtained daily from patients with persistent fever;
in cases of established bacteremia, samples were
obtained until the blood culture results were negative.
All bacterial isolates were tested for in vitro suscepti-
bility to imipenem/cilastatin using the Kirby-Bauer
disc diffusion method or by determining minimum
internal controls (MICs), as recommended by the
National Committee on Clinical Laboratory Stan-
dards (NCCLS) [14]. Primary febrile episodes were
classified according to guidelines issued by the IHS
Consensus Conference and the ESCMID [11].
From June 2001 to June 2002, patients received i.v.
imipenem/cilastatin as initial antibiotic therapy at
a dosage of 500 mg every 6 hours (group I). From
July 2002 to December 2003, patients received imipe-
nem/cilastatin in combination with a glycopeptide
consisting of vancomycin (1 g every 12 hours, 99 cases)
or teicoplanin (400 mg/day, 132 cases) (group I 1 G).
Patients received antibiotic therapy for a minimum of
7 days in total and for at least 4 days after their last
fever. Group I patients were given glycopeptide (van-
comycin or teicoplanin) if a fever persisted for 72
hours. Antifungal therapy was commenced if patients
remained febrile or if their clinical status worsened
after 4 to 6 days of antibiotic therapy.The primary endpoint of the study was the re-
sponse rate in the absence of treatment modification
72 hours after the initial antimicrobial treatment.
Secondary endpoints were response rates after modi-
fication of the initial antibiotic regimen (overall
response), response rates in microbiologically docu-
mented infection (MDI), fever of unknown origin
(FUO), time to response, and overall mortality.
Response was assessed 72 hours after treatment (early
response) and at completion of therapy (final response).
A treatment was categorized having a successful re-
sponse if all of the following criteria were met: afebrile
(\38C) for 4 consecutive days, abatement of signs and
symptoms of infection, eradication of the infecting mi-
croorganism (when present), and no recurrence of the
primary infection at 1 week after completion of treat-
ment. Treatment failure was defined as: (1) death
from primary infection, (2) modification of the initial
antibacterial treatment to eradicate the primary infec-
tion, and (3) in vitro resistance to the b-lactam agent.
A patient’s response was considered nonassessable in
the following circumstances: (1) coexistent fungal or vi-
ral infection, (2) febrile episode not related to infection,
and (3) protocol violation (nonadherence to the proto-
col or early discontinuation of treatment because of
severe adverse effects).
Adverse events were graded according to theWorld
HealthOrganization (WHO) grading system [15]. Sec-
ondary infection was defined as an infection caused by
amicroorganismother than the initial pathogen that de-
veloped during antibiotic therapy or within 1 week of
discontinuation of antibiotic treatment.
All data were analyzed using the 4F and 3D rou-
tines of the Biomedical Data Package (BMDP,Univer-
sity of California, Berkeley, CA) [16]. Fisher’s exact
test, the chi-square test, Student’s t-test, and Mann-
Whitney’sU test were used to test differences between
end point means. Values of P\ .05 were considered
statistically significant.RESULTS
Four hundred twenty-eight patients who met all
the inclusion/exclusion criteria were included in the
study; group I consisted of 197 patients and group I
1 G consisted of 231 patients. Demographic data are
shown in Table 1. All but 10 patients received ASCT
involving peripheral blood stem cells (PBSCs). The
duration of neutropenia (\1  109/L) in group I 1
G did not differ from that in group I (11.3 days versus
10.9 days, P 5 .12).
FUO accounted for 33.5% of episodes in group I
and 50% of episodes in group I 1 G (P 5 .005).
Clinically documented infections (CDI) were ob-
served in 66 patients and 53 patients in groups I
and I 1 G, respectively (P 5 .01). The prevalence
Table 1. Patient Characteristics
Treatment Group
No. of Patients
Total (%) I (n 5 197) I + G (n 5 231)
Age (years)
Mean† 48.4 51.1
Median 51 53
Range 20-70 18-74
Sex
Male 114 (58) 127 (55)
Female 83 (42) 104 (45)
Underlying disease‡
Multiple myeloma 179 (42) 69 (35) 110 (48)
Lymphoma 167 (39) 90 (46) 77 (33)
Acute leukemia 59 (13) 28 (14) 31 (13)
Other‡ 23 (6) 10 (5) 13 (6)
Oral prophylaxis§
None 157 (37) 76 (39) 81 (35)
Fluoroquinolone 158 (37) 57 (29) 101 (44)
Cotrimoxazole 71 (16) 36 (18) 35 (15)
Fluoroquinolone +
Cotrimoxazole
35 (8) 23 (11) 12 (5)
Others 7 (2) 5 (3) 2 (1)
Use of growth
factors (G-CSF)¶
Yes 357 (85) 154 (79) 203 (89)
Type of central venous line
before onset of fever
Port-a-Cath or Hickman 110 (33) 57 (38.5) 53 (29)
Central 205 (62) 80 (54) 125 (69)
Peripheral 14 (5) 11 (7.5) 3 (2)
Use of total
parenteral nutrition
Yes 157 (39) 70 (37) 87 (40)
Mucositis at start of
intravenous antibiotics
Absent 67 (16) 27 (14) 40 (17)
Present 361 (84) 170 (86) 191 (83)
I indicates Imipenem/cilastatin; I + G: Imipenem/cilastatin plus glycopep-
tides; G-CSF, granulocyte-colony stimulating factor.
*Other diagnoses: primary amyloidosis (9 cases); solid tumors (8 cases);
myelodysplastic syndrome (3 cases); B- cell? prolymphocytic leukemia (1
case); chronic myelogenous leukemia (1 case); POEMS syndrome (1
case).
†P 5 .04.
‡P 5 .008.
§P 5 .09.
¶P 5 .006.
Table 2. Type of Infection According to Treatment Group
Type of Infection
I (n 5 197)
No. of
Patients (%)
I+G (n 5 231)
No. of
Patients (%) P
Fever of unknown origin 66 (33.5) 116 (50) .005
Clinically documented infection 66 (33.5) 53 (23) .01
Bacteremia* 55 (28) 51 (22)
Gram-positive 34 28
Gram-negative 15 15
Microbiologically documented
infection†
10 (5) 11 (5)
I indicates Imipenem/cilastatin; I + G: Imipenem/cilastatin plus glycopep-
tide;
*There were 6 and 8 cases of polymicrobial bacteremia in Groups I and I
+ G, respectively.
†Without bacteremia.
Table 3. Isolated Pathogens in Bacteremia According to
Treatment Group
Pathogen I I + G
CNS 29 22
Escherichia coli 7 14
KES 4 2
Streptococcus spp 3 7
Pseudomonas spp 4 2
Staphylococcus aureus 2 3
Other Gram-positive 9 6
Other Gram-negative 6 5
I indicates Imipenem/cilastatin; I + G, Imipenem/cilastatin plus glycopep-
tide; CNS, coagulase-negative staphylococci; KES, Klebsiella, Entero-
bacter, Serratia.
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I 1 G (P 5 .16) (Table 2). There were 6 and 8 cases
of polymicrobial bacteremia in the I and I 1 G
groups, respectively. Table 3 lists microorganisms
isolated from bacteremia patients according to the
treatment groups.
Breakthrough infections were observed in 56
patients; 29 in group I, and 27 in group I1G (P5 ns).
Resolution of fever without modification to ther-
apy was observed in 108 patients (55%) and 159
patients (69%) in groups I and I 1 G, respectively
(P5 .003). Themost frequentmodifications to the ini-
tial antimicrobial regimens were the addition of glyco-
peptide (56 patients in group I) and the addition of
amikacin (19 patients in group I and 18 patients in
group I 1 G). The median time to defervescence was4 days (range: 1-40 days) for group I and 4 day (range:
2-36 days) for group I 1 G (P 5 ns).
The response in patients presenting with FUOwas
70% in group I and 74% in group I1G (P5 ns).With
respect to MDI, a higher response rate among Gram-
positive bacteremias was observed in group I1G than
in group I (68% versus 29%, respectively; P 5 .0025;
Table 4). Eight and 18 patients of groups I and I 1
G, respectively, received antifungal agents (P 5 .1).
Five (1.2%) of the 428 patients died, and mortality
rate did not differ significantly between groups.
Adverse events were associated with antibiotics in 7
(3.5%) patients in group I, and in 12 (5.2%) in group
I 1 G.
The median duration of hospitalization was 26
days (range: 18-96 days) in group I and 26 days (range:
10-84 days) in group I 1 G (P 5 ns). The median and
range of the duration of hospitalization after com-
mencement of antibiotic administration was 12.6
days (2-42 days) in group I and 12.2 days (2-51 days)
in group I 1 G (P 5 .28). Fifty-six patients in group
I received glycopeptides for 9 days; the median dura-
tion of glycopeptide therapy for the 231 patients in
group I1Gwas 8 days. The cost of glycopeptide ther-
apy for group I was 26,495.56 V (135.49 V/patient)
and the median cost of glycopeptide therapy for group
I 1 G was 64,283.44 V (278.28 V/patient).
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This study shows that empirical monotherapy with
imipenem/cilastatin is an effective approach for neu-
tropenic patients with fever after ASCT. The addition
of a glycopeptide to the initial antimicrobial therapy
does not reduce mortality, duration of hospitalization,
or time to defervescence, and it increases the cost of
therapy.
Our results show that in ASCT recipients, inclusion
of a glycopeptide in the initial antibiotic regimen for fe-
brile neutropenia results in a high success rate and abro-
gates the need to modify the initial regimen. Because
coagulase-negative staphylococci are present in most
patients with MDI, the inclusion of a glycopeptide in
first-line therapy might be considered for ASCT
patients. In our series, 56 patientswho developed persis-
tent fever and who were not treated initially with glyco-
peptides subsequently required glycopeptide treatment.
However, because of the nonblinded nature of our
study, the success rate without modification should be
interpreted cautiously. On the other hand, glycopeptide
addition had no effect on clinically relevant endpoints
such as time to defervescence, incidence of break-
through infections, and mortality rate, as patients with
Gram-positive bacteremia were appropriately treated
without an increase in morbidity or mortality.
The higher incidence of FUO in group I 1 G was
probably because of the early addition of a glycopep-
tide, which probably prevented the growth of Gram-
positive bacteria in blood cultures. Conversely, more
patients in group I presented with CDI.
Some authors have recommended the administra-
tion of glycopeptide for patients with febrile neutrope-
nia who are at high risk of shock or respiratory distress
syndrome associated with viridans streptococcal infec-
tions [17-20]. However, these complications occur
infrequently when a carbapenem is used [21-25]. In
fact, our study shows that none of the cases of febrileTable 4. Clinical Response and Time to Defervescence Ac-
cording to Treatment Group
I (n 5 197)
No. of
Patients (%)
I + G (n 5 231)
No. of
Patients (%)
Complete response to first-line
antimicrobial therapy
108 (55) 159 (69)
Complete response in patients with FUO 46 (70) 86 (74)
Complete response in patients with
bacteremia*
20 (36) 32 (63)
Gram-positive† 10 (29) 19 (68)
Gram-negative 7 (47) 8 (53)
Polimicrobial 3 (50) 5 (62.5)
Overall response after modification 86 (97) 70 (97)
Median time to defervescence (days) 4 (range 1-40) 4 (range 2-36)
I indicates imipenem/cilastatin; I + G, imipenem/cilastatin plus glycopep-
tide; FUO, fever of unknown origin.
*P 5 .006.
†P 5 .0025.neutropenia was accompanied by shock or severe sep-
sis, probably because of the use of imipenem/cilastatin
as initial antibiotic regimen. These findings suggest
that the systematic use of glycopeptides is not justified
in patients undergoing ASCT, at least when treated
with imipenem/cilastatin. However, the addition of
a glycopeptide and amikacin should be taken into con-
sideration as initial antimicrobial therapy for patients
who present with septic shock or acute respiratory
distress syndrome.
Our data suggest that it is cost-effective to with-
hold glycopeptide treatment during the first 3 days
of febrile neutropenia or until Gram-positive blood
cultures are grown [9]. In addition, a reduction in the
use of glycopeptides would help to retard the emer-
gence of glycopeptide-resistant organisms.
In conclusion, our study shows that in ASCT
recipients, inclusion of a glycopeptide in the initial
antibiotic regimen for febrile neutropenia results in
an increase of the antibiotic therapy costs, without
benefits in terms of clinically relevant endpoints such
as the interval to defervescence, incidence of break-
through infection, and mortality rate.ACKNOWLEDGMENTS
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